口服或静滴VP-16联合CTX、ADM和PDN方案治疗NHL疗效和毒性观察

Comparison of the Therapeutic Effects of Oral or Intravenous VP-16 plus CTX ADM and PDN Regimen for Non-Hodgkin's Lymphoma

目的 比较口服VP -16,静滴VP -16联合环磷酰胺 (CTX) ,阿霉素 (ADM)和强的松 (PDN)方案 (CHEP方案 )治疗非霍奇金淋巴瘤的临床疗效和毒性。方法 采用CHEP方案治疗非霍奇金淋巴瘤 47例 ,VP -16口服组 2 3例 ,针剂组 2 4例 ,均为初治患者 ,均经病理细胞学证实 ,每 3～ 4周为一疗程。结果 治疗组及对照组的完全缓解率分别为 3 9 1% (9/2 3 )和 41 7% (10 /2 4) ,总有效率分别为 73 9% (17/2 3 )和 79 2 % (19/2 4) ,两组相比均无显著性差异 (P >0 0 5 )。两组主要毒性为骨髓抑制、脱发、轻度胃肠道反应。结论 口服或静滴VP -16联合CTX。

Objective To evaluate the clinic results of oral or intravenous VP-16 plus cyclo-phosphamide (CTX),Adriamycin(ADM),and prednisone (PDN) regimen for non-Hodgkin's lymphoma (NHL). Methods 47 cases of cytological and pathological confirmed advanced NHL were treated with CHEP regimen,the patients were randomly divided into two groups. 23 Cases with non-Hodgkin's lymphoma were in oral group,while 24 cases were in iv drip group.All patients received no previous treatment.Treatment was repeated every 3～4 weeks for the two groups.Results The complete response rate of the two groups were 39.1% (9/23) and 41.7% (10/24).The overall response rates of the two groups were 73.9%(17/23) and 79.2%(19/24).The were no statistically significant difference between the two groups ( P >0 05).The major toxic effects were gastrointestinal reaction,alopecia and similar myelosuppession.Conclusions The combined chemotherapy Oral or intravenous VP-16 plus cyclophosphamide(CTX),Adriamycin (ADM),and prednison (PDN) regimen is worthy of use in the treatment of non-Hodgkin's lymphoma.